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Nonsmall cell lung cancer (NSCLC) is diagnosed in the
majority of patients in advanced stage of disease. In this
setting, the prognosis is very poor with median survival of 9–
12 months and palliative chemotherapy being the standard
of care. However, chemotherapy in advanced disease seems
to have reached a plateau with no doublet combination
shown to be clinically superior to the others. Advances in the
knowledgeoftumorbiologyandmechanismsofoncogenesis
has granted the singling out of several molecular targets
for NSCLC treatment. Targeted therapies are designed to
interfere with speciﬁc aberrant biologic pathways involved
in tumorigenesis. A large amount of preclinical in vivo
and in vitro data have been gathered on the antitumor
p r o p e r t i e so fan u m b e ro fn e wb i o l o g i c a la g e n t s ,b o t h
as single agents and combined with other conventional
treatment modalities such as chemotherapy. Several targeted
therapies have been introduced in cancer treatment, and
in particular geﬁtinib and erlotinib—two epidermal growth
factor receptor tyrosine kinase inhibitors (EGFR TKI) and
bevacizumab (an antiangiogen agent) have been introduced
in advanced NSCLC, and others are in current clinical
development.
The present issue includes 5 papers dedicated to targeted
therapies of NSCLC, 2 on basic science and 3 focusing
on medical treatment. The ﬁrst paper by K. S. S. Enﬁeld
et al. deals with the role of microRNA gene dosage alter-
ation assessment in order to deﬁne potential tumor drug
resistance and response to chemotherapy. The authors, by
instigating a logical stepwise strategy, have identiﬁed speciﬁc
microRNAs that are associated with resistance to several
chemotherapeutic agents and provide a proof-of-principle
demonstration of how these various databases may be
exploited to derive relevant pharmacogenomic results. The
second paper is a complete review on targeted therapies in
NSCLC.Theauthorsdescribetheidentiﬁedtumortargetand
biomarkers opening the ﬁeld of personalized medicine. They
deal with already registered drugs in current clinical practice
and the new agents under current investigation. R. Costanzo
et al. in the third paper reviewed the role of geﬁtinib in
the treatment of advanced NSCLC harbouring an activating
EGFR mutation. Geﬁtinib and erlotinib can be considered
the standard ﬁrst-line treatment in this subgroup of patients
based on their superiority showed in terms of progression-
free survival, response rate, and quality of life as compared to
chemotherapy. To date geﬁtinib has provided data on Asians
only and has not been approved in the USA while erlotinib,
with data on both Asians and Caucasians, has been approved
worldwide.
When added to chemotherapy, continuous treatment
with tyrosine kinase inhibitors (TKIs) oﬀers no beneﬁt in
comparison with chemotherapy alone. This may be due
to the antagonistic eﬀect of TKIs and chemotherapy: cells
are pushed into the G-0 phase of the cell cycle and are
therefore resistant to cytotoxic drugs. In the fourth paper
M. Zwitter et al. report the results of a phase II study in
patients with advanced NSCLC with EGFR mutation using
an intermittent schedule of erlotinib and chemotherapy
with cisplatin plus gemcitabine in order to overcome the
previously described negative interference of drugs. The
authors observed even on a small patients’ population2 Journal of Biomedicine and Biotechnology
interestingresultsandmildtoxicity.Inthelast,paperEscobar
M.etal.makeastate-of-the-artreviewbasedontheavailable
literature regarding the use of bortezomib as a single agent
or in combination with chemotherapy in patients with lung
cancer. The ubiquitin-proteasome system like other cellular
pathways is critical for the proliferation and survival of
cancer cells; thus, proteosome inhibition has become a very
attractive anticancer therapy.
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